Open AccessRidogrel: An Antiplatelet Agent with Antihypertensive Properties
Author(s) -
Wilson Thomas W.,
Quest Dale W.
Publication year - 2000
Publication title -
cardiovascular drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3466
pISSN - 0897-5957
DOI - 10.1111/j.1527-3466.2000.tb00045.x
Subject(s) - thromboxane , antithrombotic , losartan , pharmacology , aspirin , medicine , thromboxane a synthase , platelet , thromboxane a2 , thromboxane receptor , ex vivo , in vivo , angiotensin ii , receptor , chemistry , in vitro , biochemistry , biology , microbiology and biotechnology
Ridogrel is a member of the class of drugs known as thromboxane receptor antagonists/thromboxane synthase inhibitors or TRASIs. In vitro and in vivo studies have confirmed it selectively reduces thromboxane A 2 (TXA 2 ) synthesis in platelets and elsewhere, while leaving the synthesis of other eicosanoids unchanged or even increased. Theoretically, it should produce a greater overall antithrombotic effect than aspirin. Some animal and human studies support this concept. A large phase III study confirmed the safety and efficacy of ridogrel in patients following myocardial infarction. It may also be useful in other clinical situations. In spontaneously hypertensive‐stroke prone rats, ridogrel reduces blood pressure, but increases plasma renin activity. The antihypertensive effect is potentiated by losartan. an angiotensin‐type I receptor antagonist. Ridogrel may also have efficacy in pregnancy induced hypertension, inflammatory bowel disease, and asthma.